News & Updates

Featured in FiercePharma, new Harris Poll findings reveal women want to be more informed by their HCPs when it comes to STIs, testing and treatment options.

BD released findings from a survey conducted online by The Harris Poll, reporting that women feel less knowledgeable about testing and treatment options for sexually transmitted infections (STIs) compared to other vaginal diseases and infections.

Dr. Jeff Andrews, VP Medical Affairs, Integrated Diagnostic Solutions, shares statistics with Business Insider about knowledge gaps in cervical cancer causes and tests.

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

In Contemporary OB/GYN, Dr. Jeff Andrews, VP Medical Affairs, shares findings from a Harris Poll noting gaps in women's knowledge about HPV and cervical cancer.

Dr. Jeff Andrews, VP Medical Affairs, Integrated Diagnostic Solutions, shares insights in POLITICO from a survey conducted by The Harris Poll noting significant gaps in women’s understanding about the causes and prevention of cervical cancer.

In this Fast Company op-ed, Brooke Story, BD Integrated Diagnostic Solutions president, challenges and encourages the advocacy for strengthening health care systems, improving testing infrastructure and delivering the highest quality care, regardless of race, geographic location, or socioeconomic status.

BD released findings from a survey conducted by The Harris Poll that indicate a significant gap in women’s knowledge about the primary causes of cervical cancer as well as the most effective means of prevention.

Simply put, cervical cancer is avoidable. The latest issue of Healthcare Purchasing News highlights how the BD Onclarity™ HPV Assay is shaping the future of women’s health and improving standards of care as the only FDA-approved HPV test that individually identifies high-risk HPV 31.

Associate Director of Medical Affairs Molly Broache notes that in today’s world where patients are catching up on missed screenings, adding pressure on already-pressured labs, it’s that much more important to take advantage of instruments and assays that do more and do better.